Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2

Xuezhu Xu, Rui Liu, Ruoyu Yang, Wanhong Zhao, Baiyan Wang, Fangxia Wang, Aili He

Blood (2024) 144 (Supplement 1): 2411.1.

https://doi.org/10.1182/blood-2024-208950

Published: 2024

Journal Articles

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Na Zhang, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Haifeng Wu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2024-202403

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Chen Chen, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2024-201274

Published: 2024

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Journal Articles

Erastin Induces Ferrotposis in Multiple Myeloma Cells through SLC7A11-IRF1-Txn Axis

Jiaxi Liu, Rui Liu, Ru Zhang, Meng Zhai, Xuezhu Xu, Xiaomin Ren, Jiyu Miao, Aili He

Blood (2024) 144 (Supplement 1): 6853.

https://doi.org/10.1182/blood-2024-209081

Published: 2024

Journal Articles

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Xuezhu Xu, Rui Liu, Ruoyu Yang, Aili He, Wanhong Zhao, Fangxia Wang

Blood (2024) 144 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2024-209034

Published: 2024

Journal Articles

Single-Center Experience of Venetoclax Combined with Azacitidine in Young Patients with Newly Diagnosed Acute Myeloid Leukemia

Xuezhu Xu, Rui Liu, Ruoyu Yang, Fangxia Wang, Wanhong Zhao, Aili He

Blood (2024) 144 (Supplement 1): 7942.

https://doi.org/10.1182/blood-2024-209174

Published: 2024

Journal Articles

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Biping Deng, Zhaoli Liu, Xiaoming Qu, Yu'e Zhang, Zhongxin Zhang, Rong Luan, Lingli Zhang, Ming Ma, Xiai Wu, Rui Liu, Alex H. Chang, Kai Hu, Chunrong Tong

Blood (2024) 144 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2024-203423

Published: 2024

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Rui Liu, Fan Yang, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2023-184692

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Teng Xu, Fan Yang, Rui Liu, Zhonghua Fu, Na Li, Xiaoyan Ke, Shaomei Feng, Biping Deng, Kai Hu

Blood (2023) 142 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2023-185590

Published: 2023

Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood (2023) 142 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2023-180809

Published: 2023

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma

Xin Li, Qian Cheng, Rui Liu, Liqing Kang, Nan Xu, Minghao Li, Lei Yu

Blood (2021) 138 (Supplement 1): 2845.

https://doi.org/10.1182/blood-2021-150477

Published: 2021

NARROW

Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Erastin Induces Ferrotposis in Multiple Myeloma Cells through SLC7A11-IRF1-Txn Axis

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Single-Center Experience of Venetoclax Combined with Azacitidine in Young Patients with Newly Diagnosed Acute Myeloid Leukemia

Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

CD20-Specific Chimeric Antigen Receptor-Expressing T Cells As Salvage Therapy in Rituximab-Refractory CD20(+) B-Cell Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only